Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6026 + enlonstobart
- Development stage
- Unknown
- Lead developer
- Suzhou Xinnuowei Pharmaceutical Technology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
SYS6026 + enlonstobart is an investigational combination therapy consisting of SYS6026, a bivalent mRNA therapeutic vaccine, and enlonstobart (SG001), a fully humanized anti-PD-1 monoclonal antibody. Developed by CSPC Pharmaceutical Group through its subsidiary CSPC Megalith Biopharmaceutical, the combination is being evaluated in Phase II clinical trials for the treatment of unresectable locally advanced or metastatic solid tumors associated with human papillomavirus (HPV) type 16 or 18. SYS6026 is designed to target the HPV E6 and E7 antigens to prime HPV16/18-specific T-cell responses, while enlonstobart blocks the PD-1 pathway to enhance and sustain these T-cell responses against the tumor cells.
- Other names
- SYS6026 + EnshuxingSYS6026 + SG001SYS6026 + SYSA1802SYS6026 and enlonstobartSYS-6026 and enlonstobartSYS 6026 and enlonstobartSYS6026 injection + enlonstobartSYS6026 injection + enlonstobart injection
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SYS6026 + enlonstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6026 + enlonstobart.